182 related articles for article (PubMed ID: 34748151)
1. Radiotherapy at oligoprogression for metastatic castration-resistant prostate cancer patients: a multi-institutional analysis.
Valeriani M; Detti B; Fodor A; Caini S; Borghesi S; Trippa F; Triggiani L; Bruni A; Russo D; Saldi S; Di Staso M; Francolini G; Lancia A; Marinelli L; Di Muzio N; Aristei C; Livi L; Magrini SM; Ingrosso G
Radiol Med; 2022 Jan; 127(1):108-116. PubMed ID: 34748151
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy.
Ingrosso G; Detti B; Fodor A; Caini S; Borghesi S; Triggiani L; Trippa F; Russo D; Bruni A; Francolini G; Lancia A; Marinelli L; Di Muzio N; Livi L; Magrini SM; Maranzano E; Musio D; Aristei C; Valeriani M
Clin Transl Oncol; 2021 Aug; 23(8):1577-1584. PubMed ID: 33495981
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.
Valeriani M; Marinelli L; Macrini S; Reverberi C; Aschelter AM; De Sanctis V; Marchetti P; Tronnolone L; Osti MF
Radiat Oncol; 2019 Nov; 14(1):205. PubMed ID: 31727093
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
5. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial.
Rans K; Joniau S; Berghen C; Goffin K; Dumez H; Haustermans K; De Meerleer G
Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38664137
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic radiotherapy to oligoprogressive lesions detected with
Onal C; Ozyigit G; Oymak E; Guler OC; Tilki B; Hurmuz P; Akyol F
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3683-3692. PubMed ID: 33693965
[TBL] [Abstract][Full Text] [Related]
7. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
8. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
9. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
12. Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR).
Valero J; Peleteiro P; Henríquez I; Conde A; Piquer T; Lozano A; Soler CC; Muñoz J; Illescas A; Jove J; Flores MM; Baquedano J; Diezhandino P; de Celis RP; Pardo EH; Samper P; Villoslada I; Eguiguren M; Millan V
Clin Transl Oncol; 2020 Aug; 22(8):1378-1389. PubMed ID: 31989474
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.
La Vecchia M; Fazio I; Borsellino N; Lo Casto A; Galanti D
Tumori; 2023 Aug; 109(4):413-417. PubMed ID: 36358013
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
15. Progression-directed Therapy for Oligoprogression in Castration-refractory Prostate Cancer.
Berghen C; Joniau S; Ost P; Poels K; Everaerts W; Decaestecker K; Haustermans K; Devos G; De Meerleer G
Eur Urol Oncol; 2021 Apr; 4(2):305-309. PubMed ID: 31558422
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer.
Massaro M; Facondo G; Vullo G; Aschelter AM; Rossi A; De Sanctis V; Marchetti P; Osti MF; Valeriani M
Front Oncol; 2021; 11():695136. PubMed ID: 34631527
[TBL] [Abstract][Full Text] [Related]
17. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
Franzese C; Perrino M; Marzo MA; Badalamenti M; Baldaccini D; D'Agostino G; Marini B; De Vincenzo F; Zucali PA; Scorsetti M
Clin Exp Metastasis; 2022 Jun; 39(3):449-457. PubMed ID: 35190933
[TBL] [Abstract][Full Text] [Related]
18. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Lohaus F; Zöphel K; Löck S; Wirth M; Kotzerke J; Krause M; Baumann M; Troost EGC; Hölscher T
Eur Urol; 2019 Apr; 75(4):548-551. PubMed ID: 30578119
[TBL] [Abstract][Full Text] [Related]
19. Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice.
Patel PH; Tunariu N; Levine DS; de Bono JS; Eeles RA; Khoo V; Murray J; Parker CC; Pathmanathan A; Reid A; van As N; Tree AC
Front Oncol; 2022; 12():862995. PubMed ID: 35656509
[TBL] [Abstract][Full Text] [Related]
20. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M
BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
